Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EPS (Weighted Average and Diluted): 2016-2017

Historic EPS (Weighted Average and Diluted) for UroGen Pharma (URGN) over the last 2 years, with Dec 2017 value amounting to $2.14.

  • UroGen Pharma's EPS (Weighted Average and Diluted) fell 52.56% to $0.74 in Q4 2017 from the same period last year, while for Dec 2017 it was $4.53, marking a year-over-year change of. This contributed to the annual value of $2.14 for FY2017, which is 12.04% up from last year.
  • According to the latest figures from FY2017, UroGen Pharma's EPS (Weighted Average and Diluted) is $2.14, which was up 12.04% from $1.91 recorded in FY2016.
  • Over the past 5 years, UroGen Pharma's EPS (Weighted Average and Diluted) peaked at $2.14 during FY2017, and registered a low of $1.91 during FY2016.
  • Over the past 2 years, UroGen Pharma's median EPS (Weighted Average and Diluted) value was $2.02 (recorded in 2016), while the average stood at $2.02.
  • Data for UroGen Pharma's EPS (Weighted Average and Diluted) shows a peak YoY rose of 12.04% (in 2017) over the last 5 years.
  • Yearly analysis of 2 years shows UroGen Pharma's EPS (Weighted Average and Diluted) stood at $1.91 in 2016, then grew by 12.04% to $2.14 in 2017.